A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, intermediate, low, low-dose-rate, monotherapy, outcome, risk, seeds | 3 Comments »
Three randomized clinical trials (Sathya et al., 2005; Hoskin et al., 2012; and Guix et al., 2013) established the combination of external beam radiation therapy (EBRT) with a high dose rate brachytherapy (HDRBT) boost as a standard of care in the treatment of high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: "high risk", brachytherapy, HDRBT, high-dose-rate, monotherapy, outcome, side effects | 10 Comments »
New registry data from the Cleveland Clinic shows good oncological control with low dose rate brachytherapy (LDRBT) monotherapy, at least for low-risk and low intermediate-risk groups. This is the first time I’ve seen LDRBT monotherapy data for higher-risk groups. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, brachytherapy, deprivation, EBRT, external, LDR, low-dose-rate, monotherapy, radiation | 6 Comments »
A currently unanswered question being addressed in clinical trials is whether the oral agent enzalutamide (Xtandi) is effective and safe as monotherapy in the treatment of progressive, hormone-naive prostate cancer (i.e., before the use of other drugs such as the LHRH agonists and other forms of androgen deprivation therapy [ADT]). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: enzalutamide, hormone-naive, monotherapy | 2 Comments »
A critical question for men with progressive prostate cancer is whether the newer types of androgen deprivation therapy (ADT, e.g., abiraterone acetate and enzalutamide) can or should be used prior to standard forms of ADT (e.g., an LHRH agonist or antagonist or antiandrogen monotherapy) in the treatment of high-risk or progressive prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, enzalutamide, monotherapy, naive | 5 Comments »
A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, castration-resistance, LHRH, monotherapy, regimen | 1 Comment »
In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, monotherapy, pprophylaxis, tamoxifen | 1 Comment »
We have separately addressed data from a 15-year follow-up of a population-based Swedish screening study. Other reports today deal with:
Filed under: Management, Prevention, Risk, Treatment | Tagged: anti-androgen, brachytherapy, diet, erectile function, maximal androgen deprivation, monotherapy, potency, prediction, risk, supplement, surgery, zinc | Leave a comment »
